Compare TPCS & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPCS | RNXT |
|---|---|---|
| Founded | 1956 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.1M | 79.4M |
| IPO Year | 2008 | 2021 |
| Metric | TPCS | RNXT |
|---|---|---|
| Price | $5.30 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 24.4K | ★ 1.4M |
| Earning Date | 02-17-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.38 | 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,644,000.00 | $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | N/A | $279.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $2.88 | $0.70 |
| 52 Week High | $6.31 | $2.59 |
| Indicator | TPCS | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 51.20 |
| Support Level | $5.12 | $0.83 |
| Resistance Level | $5.69 | $2.59 |
| Average True Range (ATR) | 0.22 | 0.22 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 24.70 | 13.41 |
Techprecision Corp manufactures precision, large-scale fabricated and machined metal structural components and systems. The company provides end-to-end services, transforming raw materials into precision finished products through custom fabrication, precision machining, assembly, integration, inspection, non-destructive evaluation, and testing. It manufactures products in accordance with customers' drawings and specifications while complying with applicable national and international industry codes and standards. Its segments are: Ranor, which generates the majority of revenue, and Stadco, both focused on the manufacture and assembly of components mainly for defense and other precision industrial customers.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.